RT Journal Article
T1 Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.
A1 Guerreiro Stucklin, Ana S
A1 Ryall, Scott
A1 Fukuoka, Kohei
A1 Zapotocky, Michal
A1 Lassaletta, Alvaro
A1 Li, Christopher
A1 Bridge, Taylor
A1 Kim, Byungjin
A1 Arnoldo, Anthony
A1 Kowalski, Paul E
A1 Zhong, Yvonne
A1 Johnson, Monique
A1 Li, Claire
A1 Ramani, Arun K
A1 Siddaway, Robert
A1 Nobre, Liana Figueiredo
A1 de Antonellis, Pasqualino
A1 Dunham, Christopher
A1 Cheng, Sylvia
A1 Boué, Daniel R
A1 Finlay, Jonathan L
A1 Coven, Scott L
A1 de Prada, Inmaculada
A1 Perez-Somarriba, Marta
A1 Faria, Claudia C
A1 Grotzer, Michael A
A1 Rushing, Elisabeth
A1 Sumerauer, David
A1 Zamecnik, Josef
A1 Krskova, Lenka
A1 Garcia Ariza, Miguel
A1 Cruz, Ofelia
A1 Morales La Madrid, Andres
A1 Solano, Palma
A1 Terashima, Keita
A1 Nakano, Yoshiko
A1 Ichimura, Koichi
A1 Nagane, Motoo
A1 Sakamoto, Hiroaki
A1 Gil-da-Costa, Maria Joao
A1 Silva, Roberto
A1 Johnston, Donna L
A1 Michaud, Jean
A1 Wilson, Bev
A1 van Landeghem, Frank K H
A1 Oviedo, Angelica
A1 McNeely, P Daniel
A1 Crooks, Bruce
A1 Fried, Iris
A1 Zhukova, Nataliya
A1 Hansford, Jordan R
A1 Nageswararao, Amulya
A1 Garzia, Livia
A1 Shago, Mary
A1 Brudno, Michael
A1 Irwin, Meredith S
A1 Bartels, Ute
A1 Ramaswamy, Vijay
A1 Bouffet, Eric
A1 Taylor, Michael D
A1 Tabori, Uri
A1 Hawkins, Cynthia
AB Infant gliomas have paradoxical clinical behavior compared to those in children and adults: low-grade tumors have a higher mortality rate, while high-grade tumors have a better outcome. However, we have little understanding of their biology and therefore cannot explain this behavior nor what constitutes optimal clinical management. Here we report a comprehensive genetic analysis of an international cohort of clinically annotated infant gliomas, revealing 3 clinical subgroups. Group 1 tumors arise in the cerebral hemispheres and harbor alterations in the receptor tyrosine kinases ALK, ROS1, NTRK and MET. These are typically single-events and confer an intermediate outcome. Groups 2 and 3 gliomas harbor RAS/MAPK pathway mutations and arise in the hemispheres and midline, respectively. Group 2 tumors have excellent long-term survival, while group 3 tumors progress rapidly and do not respond well to chemoradiation. We conclude that infant gliomas comprise 3 subgroups, justifying the need for specialized therapeutic strategies.
YR 2019
FD 2019-09-25
LK http://hdl.handle.net/10668/14546
UL http://hdl.handle.net/10668/14546
LA en
DS RISalud
RD Apr 17, 2025